More recently, a computational study found that SGLT2is (Canagliflozin and Empagliflozin) displayed binding affinity and stability to the distal ubiquitin-binding domain, serving as possible inhibitors of the ubiquitin-specific protease 30 or USP30 that plays a crucial role in the pathogenesis of mitochondrial dysfunction in PD [315]. Here, USP30 is linked to Parkinson disease.